Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment
Angioimmunoblastic T-cell lymphoma (AITL) is a malignancy with very poor survival outcome, in urgent need of more specific therapeutic strategies. The drivers of malignancy in this disease are CD4+ follicular hel... (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - February 6, 2024 Category: Cancer & Oncology Authors: Adrien Krug, Marie Tosolini, Blandine Madji Hounoum, Jean-Jacques Fourni é, Roger Geiger, Matteo Pecoraro, Patrick Emond, Philippe Gaulard, François Lemonnier, Jean-Ehrland Ricci and Els Verhoeyen Tags: Research Source Type: research
The fecal bacterial microbiota is not useful for discriminating between lymphoplasmacytic enteritis and low-grade intestinal T-cell lymphoma in cats nor for predicting therapeutic response
Am J Vet Res. 2024 Feb 9:1-9. doi: 10.2460/ajvr.23.11.0251. Online ahead of print.ABSTRACTOBJECTIVE: To evaluate the fecal bacterial microbiota at the time of diagnosis (T0) and after 1 month of therapy (T1) in cats diagnosed with lymphoplasmacytic enteritis (LPE) or cats with low-grade intestinal T-cell lymphoma (LGITL) and to compare these findings with those of healthy cats.ANIMALS: 5 healthy cats, 13 cats with LPE, and 7 cats with LGITL were prospectively enrolled between June 2020 and June 2021.METHODS: Fecal samples were collected at T0 and T1, and DNA was extracted for 16S ribosomal amplicon sequencing. Alpha divers...
Source: American Journal of Veterinary Research - February 5, 2024 Category: Veterinary Research Authors: Elena Benvenuti Riccardo Ferriani Paola Gianella Pietro Ruggiero Federica Cagnasso Antonio Borrelli Giuseppe Benvenuto Loris Bertoldi Enrico Bottero Source Type: research
< em > Erratum to < /em > : Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization
Haematologica. 2024 Feb 1;109(2):693-694. doi: 10.3324/haematol.2024.285005.NO ABSTRACTPMID:38299726 | PMC:PMC10828768 | DOI:10.3324/haematol.2024.285005 (Source: Haematologica)
Source: Haematologica - February 1, 2024 Category: Hematology Authors: Kerry J Savage Laurence De Leval Source Type: research
< sup > 18 < /sup > F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study
CONCLUSIONS: 18F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.PMID:38299464 | DOI:10.1080/17474086.2024.2313457 (Source: Expert Review of Hematology)
Source: Expert Review of Hematology - February 1, 2024 Category: Hematology Authors: Raul Cordoba Joaqu ín Sánchez-García Eva Domingo-Domenech Javier L ópez Jiménez Antonio Mart ínez Pozo Cecilia Carpio Ángeles Bendaña Ana Julia Gonz ález Sonia Gonz ález de Villambrosia Jos é Gómez Codina Bel én Navarro Guillermo Rodr íguez Source Type: research
Construction and in Vitro Evaluation of a Novel Anti-CD25 Chimeric Antigen Recepto
The interleukin-2 (IL-2) receptor has been an attractive target to treat hematologic malignancies for decades, in as much as CD25 is expressed on lymphoma or leukemia cells of T- and B-cell origin, including Adult T-cell leukemia/lymphoma, chronic lymphocytic leukemia, cutaneous T-cell lymphoma (CTCL), Hodgkin's disease, as well as B-cell non-Hodgkin's lymphoma. To date, there are no FDA approved chimeric antigen receptor T-cells (CAR-T) that treat T-cell neoplasms, so an effective CAR-T that targets a T-cell neoplasm such as Adult T-cell leukemia/lymphoma, is direly needed. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ira Braunschweig Tags: 225 Source Type: research
